Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

STOKStoke Therapeutics, Inc.

Nasdaq · CIK 0001623526
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts204

Identity from submissions API

NameStoke Therapeutics, Inc.
CIK0001623526
TickersSTOK
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN471144582
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone781-430-8200
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • ASOthera Pharmaceuticals, Inc. (2014-11-24T05:00:00.000Z → 2014-11-24T05:00:00.000Z)
Business address
45 WIGGINS AVENUE
BEDFORD
MA
01730
MA
Mailing address
45 WIGGINS AVENUE
BEDFORD
MA
01730
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

636 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-128366 005-91051 261561462 34 15908
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000902219-26-000384 005-91051 261557887 34 17322
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001493215-26-000208 005-91051 261555756 34 11163
2026-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000895421-26-000321 005-91051 261553412 34 12323
2026-11-05 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000315066-26-002860 005-91051 261526343 34 11675
2026-11-04 4 xslF345X06/form4-11042026_041102.xml 0001780088-26-000025 7308
2026-11-03 10-Q 10-Q 0001193125-26-445326 001-38938 261517331 34 10217005 1 1
2026-10-29 8-K 8-K 2.02,9.01 0001193125-26-437775 001-38938 261501677 34 556142 1 1
2026-10-21 144 xsl144X01/primary_doc.xml 0001950047-26-010349 001-38938 261476202 33 14072
2026-10-02 4 xslF345X06/form4-10022026_091025.xml 0001966716-26-000014 4978
2026-10-02 4 xslF345X06/form4-10022026_091051.xml 0001780088-26-000023 5514
2026-10-02 144 xsl144X01/primary_doc.xml 0001950047-26-010004 001-38938 261436803 33 5488
2026-09-30 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000921895-26-002685 005-91051 261428499 34 38314
2026-09-25 4 xslF345X06/form4-09252026_080935.xml 0001685994-26-000009 5732
2026-09-25 3 xslF345X06/form3-09252026_080902.xml 0001685994-26-000007 10461
2026-09-25 8-K 8-K 5.02 0001193125-26-402820 001-38938 261410391 34 137396 1 1
2026-09-03 4 xslF345X06/form4-09032026_080910.xml 0001780088-26-000021 7309
2026-08-18 4 xslF345X06/form4-08192026_120845.xml 0001780088-26-000019 11469
2026-08-18 4 xslF345X06/form4-08192026_120851.xml 0001522780-26-000007 11467
2026-08-18 4 xslF345X06/form4-08192026_120818.xml 0001966716-26-000012 11466
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000902664-26-003525 005-91051 261282701 34 10672
2026-08-12 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000947263-26-000071 005-91051 261267557 34 11053
2026-08-06 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000315066-26-002141 005-91051 261247250 34 11668
2026-08-05 4 xslF345X06/form4-08052026_080835.xml 0001780088-26-000017 7309
2026-08-03 8-K 8-K 8.01,9.01 0001193125-26-330804 001-38938 261234288 34 174714 1 1
2026-08-03 424B5 424B5 0001193125-26-330792 333-294402 261234263 33 719614 1 1
2026-08-03 144 xsl144X01/primary_doc.xml 0001950047-26-007565 001-38938 261233871 33 6785
2026-08-03 S-8 S-8 0001193125-26-330706 333-297931 261233700 33 411964 1 1
2026-08-03 10-Q 10-Q 0001193125-26-330557 001-38938 261232888 34 9339867 1 1
2026-08-03 8-K 8-K 2.02,9.01 0001193125-26-330537 001-38938 261232796 34 543339 1 1
2026-07-17 4 xslF345X06/form4-07172026_080716.xml 0001404955-26-000006 40541
2026-07-17 4 xslF345X06/form4-07172026_080754.xml 0001858760-26-000008 5693
2026-07-17 3 xslF345X06/form3-07172026_080707.xml 0001858760-26-000007 10244
2026-07-06 4 xslF345X06/form4-07062026_080747.xml 0001780088-26-000015 7308
2026-07-01 144 xsl144X01/primary_doc.xml 0001950047-26-006742 001-38938 261146108 33 6202
2026-06-30 8-K 8-K 7.01,8.01,9.01 0001193125-26-289409 001-38938 261138055 34 166728 1 1
2026-06-18 4 xslF345X06/form4-06182026_080652.xml 0001966716-26-000010 4979
2026-06-16 144 xsl144X01/primary_doc.xml 0001950047-26-006194 001-38938 261095110 33 7564
2026-06-05 4 xslF345X06/form4-06052026_080612.xml 0001586226-26-000004 5693
2026-06-05 4 xslF345X06/form4-06052026_080637.xml 0001557928-26-000002 5676
2026-06-05 4 xslF345X06/form4-06052026_080631.xml 0001181556-26-000007 5746
2026-06-05 4 xslF345X06/form4-06052026_080620.xml 0001780081-26-000006 5692
2026-06-05 4 xslF345X06/form4-06052026_080652.xml 0001522780-26-000004 5695
2026-06-05 4 xslF345X06/form4-06052026_080609.xml 0001404955-26-000002 5670
2026-06-05 4 xslF345X06/form4-06052026_080621.xml 0001640069-26-000002 5695
2026-06-04 8-K 8-K 5.07 0001193125-26-257394 001-38938 261064979 34 141184 1 1
2026-06-03 4 xslF345X06/form4-06032026_090641.xml 0001780088-26-000013 4981
2026-05-18 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000902664-26-002559 005-91051 26995686 34 11127
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000902664-26-002530 005-91051 26988434 34 10698
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-062573 005-91051 26987808 34 12283
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000947263-26-000048 005-91051 26985428 34 10903
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001493215-26-000118 005-91051 26982595 34 11160
2026-05-15 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000902219-26-000132 005-91051 26982174 34 17180
2026-05-07 8-K 8-K 2.02,9.01 0001193125-26-212020 001-38938 26953741 34 456195 1 1
2026-05-07 10-Q 10-Q 0001193125-26-211874 001-38938 26953153 34 10379645 1 1
2026-05-05 4 xslF345X06/form4-05052026_080522.xml 0001780088-26-000011 4980
2026-05-01 144 xsl144X01/primary_doc.xml 0001950047-26-003920 001-38938 26933412 33 7577
2026-04-22 ARS ARS 0001193125-26-170416 001-38938 26883913 34 1113972
2026-04-22 DEFA14A DEFA14A 0001193125-26-170393 001-38938 26883843 34 696849
2026-04-22 DEF 14A DEF 14A 0001193125-26-170362 001-38938 26883755 34 4623575 1 1
2026-04-07 4 xslF345X06/form4-04072026_110410.xml 0001849236-26-000004 5708
2026-04-07 3 xslF345X06/form3-04072026_110409.xml 0001849236-26-000002 10245
2026-04-07 8-K 8-K 5.02,7.01,9.01 0001193125-26-145524 001-38938 26844744 34 160861 1 1
2026-04-03 4 xslF345X06/form4-04032026_080432.xml 0001780088-26-000009 4980
2026-04-01 144 xsl144X01/primary_doc.xml 0001950047-26-003143 001-38938 26828913 33 6873
2026-03-27 8-K 8-K 4.01,9.01 0001193125-26-129168 001-38938 26807869 34 141474 1 1
2026-03-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-002350 005-91051 26804605 34 7172
2026-03-24 4 xslF345X06/form4-03242026_080316.xml 0001966716-26-000008 7307
2026-03-20 144 xsl144X01/primary_doc.xml 0001950047-26-002862 001-38938 26778687 33 6171
2026-03-19 4 xslF345X06/form4-03192026_100350.xml 0001780088-26-000006 17751
2026-03-19 4 xslF345X06/form4-03192026_100335.xml 0001774690-26-000006 12340
2026-03-19 4 xslF345X06/form4-03192026_090337.xml 0001762572-26-000006 12328
2026-03-19 4 xslF345X06/form4-03192026_090304.xml 0001966716-26-000006 12330
2026-03-19 144 xsl144X01/primary_doc.xml 0001950047-26-002826 001-38938 26774495 33 5379
2026-03-18 S-3ASR S-3ASR 0001193125-26-113933 333-294402 26768930 33 1128525 1 1
2026-03-17 4 xslF345X05/form4-03172026_090347.xml 0001762572-26-000004 7436
2026-03-17 4 xslF345X05/form4-03172026_090359.xml 0001774690-26-000004 7176
2026-03-17 4 xslF345X05/form4-03172026_090316.xml 0001780088-26-000004 14775
2026-03-17 4 xslF345X05/form4-03172026_090329.xml 0001522780-26-000002 10964
2026-03-17 4 xslF345X05/form4-03172026_090341.xml 0001966716-26-000004 15038
2026-03-17 4 xslF345X05/form4-03172026_090352.xml 0001181556-26-000005 5645
2026-03-16 S-8 S-8 0001193125-26-108667 333-294359 26758067 33 203228 1 1
2026-03-16 10-K 10-K 0001193125-26-108362 001-38938 26756875 34 15736619 1 1
2026-03-13 144 xsl144X01/primary_doc.xml 0001950047-26-002580 001-38938 26752737 33 4854
2026-03-12 4 xslF345X05/form4-03122026_080323.xml 0001586226-26-000002 9117
2026-03-12 4 xslF345X05/form4-03122026_080302.xml 0001780081-26-000004 5390
2026-03-10 144 xsl144X01/primary_doc.xml 0001950047-26-002448 001-38938 26739940 33 5640
2026-03-04 4 xslF345X05/form4-03042026_090337.xml 0001780081-26-000002 5389
2026-03-03 8-K 8-K 5.02 0001193125-26-088205 001-38938 26714179 34 133264 1 1
2026-03-02 144 xsl144X01/primary_doc.xml 0001950047-26-002030 001-38938 26708526 33 4798
2026-02-19 4 xslF345X05/form4-02192026_090252.xml 0001780088-26-000002 8096
2026-02-19 4 xslF345X05/form4-02192026_090250.xml 0001197032-26-000002 8106
2026-02-19 4 xslF345X05/form4-02192026_090230.xml 0001774690-26-000002 8107
2026-02-19 4 xslF345X05/form4-02192026_090202.xml 0001762572-26-000002 8095
2026-02-19 4 xslF345X05/form4-02192026_090202.xml 0001966716-26-000002 8096
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-26-016426 005-91051 26641394 34 15062
2026-02-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-26-000519 005-91051 26602043 34 11585
2026-01-26 8-K 8-K 1.01,2.03 0001193125-26-022569 001-38938 26560573 34 134909 1 1
2026-01-12 8-K 8-K 2.02,7.01,8.01,9.01 0001193125-26-009781 001-38938 26524681 34 177002 1 1
2026-01-05 4 xslF345X05/form4-01052026_090116.xml 0001181556-26-000003 7951
2025-12-10 4 xslF345X05/form4-12102025_091230.xml 0001966716-25-000009 7172
2025-12-10 4 xslF345X05/form4-12102025_091241.xml 0001522780-25-000010 8934
2025-12-08 144 xsl144X01/primary_doc.xml 0001950047-25-009955 001-38938 251556611 33 9643
2025-12-08 144 xsl144X01/primary_doc.xml 0001950047-25-009951 001-38938 251556589 33 8948
2025-12-05 4 xslF345X05/form4-12062025_011222.xml 0001780088-25-000006 14660
2025-12-05 4 xslF345X05/form4-12062025_011216.xml 0001522780-25-000009 16648
2025-12-05 4 xslF345X05/form4-12062025_011219.xml 0001966716-25-000008 16650
2025-12-05 144 xsl144X01/primary_doc.xml 0001950047-25-009875 001-38938 251553502 33 7574
2025-12-05 144 xsl144X01/primary_doc.xml 0001950047-25-009869 001-38938 251553366 33 6874
2025-12-05 144 xsl144X01/primary_doc.xml 0001950047-25-009868 001-38938 251553362 33 7559
2025-12-05 8-K 8-K 7.01,8.01,9.01 0001193125-25-308781 001-38938 251551357 34 205548 1 1
2025-12-03 4 xslF345X05/form4-12042025_011237.xml 0001780088-25-000005 14700
2025-12-03 4 xslF345X05/form4-12042025_011205.xml 0001522780-25-000008 14688
2025-12-03 4 xslF345X05/form4-12042025_011223.xml 0001966716-25-000006 14716
2025-11-26 4 xslF345X05/form4-11262025_091144.xml 0001780081-25-000006 5391
2025-11-24 144 xsl144X01/primary_doc.xml 0001950047-25-009261 001-38938 251513372 33 5504
2025-11-18 4 xslF345X05/form4-11182025_091122.xml 0001780081-25-000004 7174
2025-11-14 144 xsl144X01/primary_doc.xml 0001950047-25-008873 001-38938 251486988 33 4797
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001771015-25-000011 005-91051 251482935 34 6969
2025-11-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000947263-25-000009 005-91051 251482900 34 7167
2025-11-05 4 xslF345X05/form4-11052025_091154.xml 0001780088-25-000004 10458
2025-11-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-002853 005-91051 251452824 34 11590
2025-11-04 10-Q 10-Q 0001193125-25-264720 001-38938 251449292 34 9531865 1 1
2025-11-04 8-K 8-K 2.02,9.01 0001193125-25-264644 001-38938 251448919 34 482431 1 1
2025-11-03 144 xsl144X01/primary_doc.xml 0001950047-25-008382 001-38938 251444434 33 6877
2025-10-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-25-002708 005-91051 251401890 34 10974
2025-10-14 4 xslF345X05/form4-10142025_081006.xml 0001197032-25-000004 8115
2025-10-10 4 xslF345X05/form4-10102025_081021.xml 0001522780-25-000007 8826
2025-10-08 144 xsl144X01/primary_doc.xml 0001950047-25-007849 001-38938 251382548 33 8305
2025-10-07 4 xslF345X05/form4-10072025_081055.xml 0001522780-25-000004 5362
2025-10-07 4 xslF345X05/form4-10072025_081001.xml 0001966716-25-000004 9319
2025-10-06 8-K 8-K 5.02,9.01 0001193125-25-230925 001-38938 251375616 34 260094 1 1
2025-10-03 144 xsl144X01/primary_doc.xml 0001950047-25-007743 001-38938 251374484 33 7598
2025-10-03 144 xsl144X01/primary_doc.xml 0001950047-25-007742 001-38938 251374402 33 8535
2025-10-03 4 xslF345X05/form4-10032025_081034.xml 0001780088-25-000003 5400
2025-10-01 4 xslF345X05/form4-10012025_081019.xml 0001181556-25-000006 7955
2025-09-18 8-K/A 8-K/A 5.07 0001193125-25-207401 001-38938 251323516 34 140456 1 1
2025-09-05 4 xslF345X05/form4-09052025_080918.xml 0001415889-25-023792 8987
2025-09-03 4 xslF345X05/form4-09032025_090900.xml 0001415889-25-023591 5400
2025-09-03 4 xslF345X05/form4-09032025_090950.xml 0001415889-25-023590 8657
2025-09-03 4 xslF345X05/form4-09032025_090917.xml 0001415889-25-023589 16101
2025-09-02 144 xsl144X01/primary_doc.xml 0001950047-25-006649 001-38938 251286111 33 8909
2025-08-29 144 xsl144X01/primary_doc.xml 0001950047-25-006558 001-38938 251281129 33 6811
2025-08-29 144 xsl144X01/primary_doc.xml 0001950047-25-006555 001-38938 251281115 33 7013
2025-08-26 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001123292-25-000387 005-91051 251258919 34 34004
2025-08-20 4 xslF345X05/form4-08202025_080828.xml 0001415889-25-022442 5142
2025-08-20 4 xslF345X05/form4-08202025_080810.xml 0001415889-25-022441 5103
2025-08-20 4 xslF345X05/form4-08202025_080802.xml 0001415889-25-022440 5142
2025-08-18 4 xslF345X05/form4-08192025_120854.xml 0001415889-25-022227 9494
2025-08-18 4 xslF345X05/form4-08192025_120830.xml 0001415889-25-022226 9490
2025-08-18 4 xslF345X05/form4-08192025_120819.xml 0001415889-25-022225 9454
2025-08-15 4 xslF345X05/form4-08152025_080840.xml 0001415889-25-022074 5112
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-078641 005-91051 251219546 34 13048
2025-08-13 144 xsl144X01/primary_doc.xml 0001950047-25-005776 001-38938 251212125 33 5385
2025-08-12 10-Q 10-Q 0000950170-25-107332 001-38938 251206912 34 9486066 1 1
2025-08-12 8-K 8-K 2.02,7.01,9.01 0000950170-25-107275 001-38938 251206495 34 17924529 1 1
2025-08-11 8-K 8-K 7.01,9.01 0001193125-25-177433 001-38938 251200085 34 174734 1 1
2025-08-06 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-002118 005-91051 251188478 34 11178
2025-08-05 4 xslF345X05/form4-08052025_080805.xml 0001415889-25-021024 5400
2025-07-29 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001085146-25-004276 005-91051 251162916 34 6629
2025-07-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-002218 005-91051 251125556 34 10864
2025-07-11 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-002242 333-288583 251120049 33 1811
2025-07-10 8-K 8-K 7.01,9.01 0001193125-25-157364 001-38938 251114804 34 171727 1 1
2025-07-09 CORRESP filename1.htm 0001193125-25-157116 9790
2025-07-09 S-8 S-8 0001193125-25-157079 333-288584 251113636 33 292109
2025-07-09 S-3 S-3 0001193125-25-157072 333-288583 251113602 33 948388
2025-07-02 4 xslF345X05/form4-07022025_080730.xml 0001415889-25-019004 5400
2025-07-02 4 xslF345X05/form4-07022025_080722.xml 0001415889-25-019002 7917
2025-07-01 144 xsl144X01/primary_doc.xml 0001950047-25-004760 001-38938 251096762 33 7592
2025-06-30 UPLOAD filename1.pdf 0000000000-25-006891 377-08144 40335
2025-06-26 DRSLTR filename1.htm 0000950123-25-006123 9986
2025-06-26 DRS filename1.htm 0000950123-25-006122 377-08144 251080860 33 879181
2025-06-23 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001123292-25-000298 005-91051 251065471 34 37250
2025-06-23 3 xslF345X02/form3-06232025_080607.xml 0001415889-25-017957 17805
2025-06-06 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001123292-25-000272 005-91051 251031039 34 35193
2025-06-06 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-011153 10829
2025-06-06 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-001629 005-91051 251029169 34 11422
2025-06-04 4 xslF345X05/form4-06052025_120602.xml 0001415889-25-015702 5558
2025-06-04 4 xslF345X05/form4-06052025_120645.xml 0001415889-25-015701 5571
2025-06-04 4 xslF345X05/form4-06052025_120640.xml 0001415889-25-015700 5571
2025-06-04 4 xslF345X05/form4-06052025_120617.xml 0001415889-25-015699 5555
2025-06-04 4 xslF345X05/form4-06052025_120602.xml 0001415889-25-015698 5533
2025-06-04 4 xslF345X05/form4-06052025_120657.xml 0001415889-25-015695 5568
2025-06-04 4 xslF345X05/form4-06052025_120640.xml 0001415889-25-015693 6909
2025-06-04 8-K 8-K 5.07 0001193125-25-134882 001-38938 251023111 34 146762 1 1
2025-06-04 8-K 8-K 7.01,8.01,9.01 0001193125-25-134447 001-38938 251021874 34 12164731 1 1
2025-05-13 10-Q 10-Q 0000950170-25-070296 001-38938 25939964 34 9145419 1 1
2025-05-13 8-K 8-K 2.02,9.01 0000950170-25-069783 001-38938 25937094 34 401520 1 1
2025-05-05 4 xslF345X05/form4-05052025_080547.xml 0001415889-25-011940 6909
2025-05-01 144 xsl144X01/primary_doc.xml 0001950047-25-002674 001-38938 25903960 33 6169
2025-04-22 ARS ARS 0001193125-25-089195 001-38938 25857803 34 1158562
2025-04-22 DEFA14A DEFA14A 0001193125-25-089192 001-38938 25857741 34 1038481
2025-04-22 DEF 14A DEF 14A 0001193125-25-089188 001-38938 25857714 34 2920154 1 1
2025-04-16 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001576419-25-000003 005-91051 25843866 34 11181
2025-04-15 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-000328 005-91051 25840329 34 10715
2025-04-02 4 xslF345X05/form4-04022025_080412.xml 0001415889-25-009616 7916
2025-03-20 4 xslF345X05/form4-03202025_100340.xml 0001415889-25-008715 5524
2025-03-20 4 xslF345X05/form4-03202025_100333.xml 0001415889-25-008714 5539
2025-03-20 4 xslF345X05/form4-03202025_100358.xml 0001415889-25-008713 8082
2025-03-20 4 xslF345X05/form4-03202025_100309.xml 0001415889-25-008712 5721
2025-03-20 4 xslF345X05/form4-03202025_100313.xml 0001415889-25-008711 12070
2025-03-20 4 xslF345X05/form4-03202025_100314.xml 0001415889-25-008710 12102
2025-03-20 4 xslF345X05/form4-03202025_100334.xml 0001415889-25-008709 12102
2025-03-18 S-8 S-8 0001193125-25-056719 333-285890 25749216 33 81820
2025-03-18 4 xslF345X05/form4-03182025_080351.xml 0001415889-25-008367 11240
2025-03-18 4 xslF345X05/form4-03182025_080350.xml 0001415889-25-008359 10976
2025-03-18 4 xslF345X05/form4-03182025_080305.xml 0001415889-25-008355 10939
2025-03-18 10-K 10-K 0000950170-25-041170 001-38938 25748244 34 15961432 1 1
2025-03-18 8-K 8-K 2.02,5.02,7.01,9.01 0000950170-25-040758 001-38938 25746477 34 476699 1 1
2025-02-18 8-K 8-K 1.01,7.01,8.01,9.01 0001193125-25-028650 001-38938 25635519 34 197200 1 1
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-020494 005-91051 25623687 34 10926
2025-02-03 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000895421-25-000200 005-91051 25583091 34 12017
2025-01-07 8-K 8-K 7.01,8.01,9.01 0001193125-25-002550 001-38938 25513461 34 4183729 1 1
2025-01-02 4 xslF345X05/form4-01022025_090156.xml 0001415889-25-000084 6835
2024-12-27 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001123292-24-000417 005-91051 241586405 34 22539
2024-12-27 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-021228 10785
2024-12-23 144 xsl144X01/primary_doc.xml 0001968582-24-001221 001-38938 241575188 33 4635
2024-12-11 4 xslF345X05/form4-12112024_091233.xml 0001415889-24-028930 5435
2024-12-11 4 xslF345X05/form4-12112024_091251.xml 0001415889-24-028929 7377
2024-12-11 4 xslF345X05/form4-12112024_091247.xml 0001415889-24-028928 5110
2024-12-10 4 xslF345X05/form4-12112024_121235.xml 0001415889-24-028892 5429
2024-12-10 4 xslF345X05/form4-12112024_121243.xml 0001415889-24-028891 5428
2024-12-10 4 xslF345X05/form4-12112024_121241.xml 0001415889-24-028890 5389
2024-12-10 4/A xslF345X05/form4a-12102024_111228.xml 0001415889-24-028889 9797
2024-12-09 144 xsl144X01/primary_doc.xml 0001950047-24-009594 001-38938 241535698 33 4809
2024-12-06 8-K 8-K 7.01,8.01,9.01 0001193125-24-272559 001-38938 241533232 34 284489 1 1
2024-12-05 4 xslF345X05/form4-12052024_091203.xml 0001415889-24-028398 9499
2024-12-05 4 xslF345X05/form4-12052024_091208.xml 0001415889-24-028397 9464
2024-12-05 4 xslF345X05/form4-12052024_091200.xml 0001415889-24-028396 9503
2024-12-03 4 xslF345X05/form4-12032024_091216.xml 0001415889-24-028071 7408
2024-12-03 4 xslF345X05/form4-12032024_091257.xml 0001415889-24-028070 7100
2024-12-03 4 xslF345X05/form4-12032024_091239.xml 0001415889-24-028069 13200
2024-11-14 SC 13G/A SC 13G/A 0001104659-24-119434 005-91051 241465544 34 86678
2024-11-14 SC 13G SC 13G 0001104659-24-118991 005-91051 241462886 34 94392
2024-11-14 SC 13G/A STOKE THERAPEUTICS, INC. 0000902664-24-006512 005-91051 241457553 34 66604
2024-11-12 SC 13G/A UnitedStates_13G__StokeThera.txt 0000932471-24-001280 005-91051 241450295 34 6603
2024-11-05 4 xslF345X05/form4-11052024_091125.xml 0001415889-24-026135 9276
2024-11-05 10-Q 10-Q 0000950170-24-121445 001-38938 241427417 34 6209106 1 1
2024-11-05 8-K 8-K 2.02,9.01 0000950170-24-121068 001-38938 241425594 34 377982 1 1
2024-11-04 SC 13G/A UnitedStates_13G__StokeThera.txt 0000932471-24-000715 005-91051 241422467 34 5669
2024-11-01 144 xsl144X01/primary_doc.xml 0001950047-24-008040 001-38938 241419743 33 6453
2024-10-09 S-3ASR S-3ASR 0001193125-24-235229 333-282561 241362955 33 945638
2024-10-02 4 xslF345X05/form4-10022024_081008.xml 0001415889-24-024378 9276
2024-09-23 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-016894 10784
2024-09-23 SC 13D/A stoke13d.htm 0001123292-24-000282 005-91051 241316485 34 349104
2024-09-19 144 xsl144X01/primary_doc.xml 0001968582-24-000850 001-38938 241311251 33 4603
2024-09-10 8-K 8-K 8.01,9.01 0001193125-24-216632 001-38938 241290303 34 239544 1 1
2024-09-05 4 xslF345X05/form4-09052024_080953.xml 0001415889-24-022900 11022
2024-08-07 10-Q 10-Q 0000950170-24-092738 001-38938 241183564 34 6257948 1 1
2024-08-07 8-K 8-K 2.02,9.01 0000950170-24-092268 001-38938 241181387 34 375699 1 1
2024-08-05 4 xslF345X05/form4-08052024_080835.xml 0001415889-24-020734 9276
2024-08-01 144 xsl144X01/primary_doc.xml 0001950047-24-005746 001-38938 241167150 33 6453
2024-07-08 SC 13G us86150r1077_070824.txt 0001086364-24-008222 005-91051 241105207 34 13974
2024-07-03 4 xslF345X05/form4-07032024_080758.xml 0001415889-24-019169 7208
2024-07-03 4 xslF345X05/form4-07032024_080719.xml 0001415889-24-019168 9276
2024-07-02 144 xsl144X01/primary_doc.xml 0001950047-24-005205 001-38938 241095528 33 5517
2024-06-21 8-K 8-K 5.02 0001193125-24-165651 001-38938 241060181 34 143919 1 1
2024-06-20 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-06-20 16:00:00 9999999995-24-001910 333-280172 241058272 33 1818
2024-06-17 CORRESP filename1.htm 0001193125-24-162675 8452
2024-06-17 UPLOAD filename1.pdf 0000000000-24-006938 333-280172 40297
2024-06-13 S-3 S-3 0001193125-24-160696 333-280172 241041250 33 245903
2024-06-07 4 xslF345X05/form4-06072024_080631.xml 0001415889-24-016010 8047
2024-06-07 4 xslF345X05/form4-06072024_080616.xml 0001415889-24-016008 8072
2024-06-07 4 xslF345X05/form4-06072024_080653.xml 0001415889-24-016005 8080
2024-06-07 4 xslF345X05/form4-06072024_080658.xml 0001415889-24-015998 8080
2024-06-07 4 xslF345X05/form4-06072024_080605.xml 0001415889-24-015995 8084
2024-06-07 4 xslF345X05/form4-06072024_080638.xml 0001415889-24-015991 12554
2024-06-07 4 xslF345X05/form4-06072024_080616.xml 0001415889-24-015976 12591
2024-06-07 4 xslF345X05/form4-06072024_080629.xml 0001415889-24-015974 12507
2024-06-07 4 xslF345X05/form4-06072024_080629.xml 0001415889-24-015970 12566
2024-06-07 4 xslF345X05/form4-06072024_080627.xml 0001415889-24-015968 12522
2024-06-07 4 xslF345X05/form4-06072024_080651.xml 0001415889-24-015965 12577
2024-06-07 4 xslF345X05/form4-06072024_080608.xml 0001415889-24-015964 12522
2024-06-07 4 xslF345X05/form4-06072024_080601.xml 0001415889-24-015962 12510
2024-06-06 8-K 8-K 5.07 0001193125-24-156049 001-38938 241025048 34 149808 1 1
2024-06-05 4 xslF345X05/form4-06052024_080649.xml 0001415889-24-015559 17898
2024-05-22 4 xslF345X05/form4-05222024_080503.xml 0001415889-24-014093 16063
2024-05-22 4 xslF345X05/form4-05222024_080510.xml 0001415889-24-014087 14428
2024-05-22 4 xslF345X05/form4-05222024_080500.xml 0001415889-24-014082 16263
2024-05-20 144 xsl144X01/primary_doc.xml 0001950047-24-003917 001-38938 24964863 33 5514
2024-05-20 144 xsl144X01/primary_doc.xml 0001950047-24-003914 001-38938 24964826 33 5516
2024-05-20 144 xsl144X01/primary_doc.xml 0001950047-24-003913 001-38938 24964816 33 6043
2024-05-17 4 xslF345X05/form4-05172024_080515.xml 0001415889-24-013477 5555
2024-05-17 3 xslF345X02/form3-05172024_080541.xml 0001415889-24-013475 10445
2024-05-06 10-Q 10-Q 0000950170-24-053535 001-38938 24917484 34 5649750 1 1
2024-05-06 8-K 8-K 2.02,9.01 0000950170-24-053195 001-38938 24915518 34 342630 1 1
2024-05-03 4 xslF345X05/form4-05032024_080531.xml 0001415889-24-012173 9277
2024-05-01 144 xsl144X01/primary_doc.xml 0001950047-24-003280 001-38938 24903468 33 7129
2024-04-29 8-K 8-K 5.02 0001193125-24-122215 001-38938 24890614 34 152791 1 1
2024-04-23 ARS ARS 0001193125-24-107021 001-38938 24864925 34 11772242
2024-04-23 DEFA14A DEFA14A 0001193125-24-106991 001-38938 24864892 34 444620
2024-04-23 DEF 14A DEF 14A 0001193125-24-106979 001-38938 24864857 34 762440
2024-04-18 SC 13D/A stoke13d.htm 0001123292-24-000113 005-91051 24854522 34 177609
2024-04-18 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-008547 10781
2024-04-17 144 xsl144X01/primary_doc.xml 0001968582-24-000320 001-38938 24851280 33 4616
2024-04-11 S-8 S-8 0001193125-24-093195 333-278619 24838548 33 82703
2024-04-03 4 xslF345X05/form4-04032024_080444.xml 0001415889-24-009999 9270
2024-04-03 4 xslF345X05/form4-04032024_080414.xml 0001415889-24-009993 10565
2024-04-01 144 xsl144X01/primary_doc.xml 0001950047-24-002817 001-38938 24810054 33 5983
2024-04-01 144 xsl144X01/primary_doc.xml 0001950047-24-002782 001-38938 24809705 33 7515
2024-04-01 4 xslF345X05/form4-04012024_080416.xml 0001415889-24-009532 6927
2024-03-28 8-K 8-K 1.01,7.01,9.01 0001193125-24-080874 001-38938 24800474 34 517613 1 1
2024-03-28 424B5 424B5 0001193125-24-080862 333-265107 24800364 33 546418
2024-03-28 144 xsl144X01/primary_doc.xml 0001950047-24-002743 001-38938 24799778 33 4805
2024-03-28 FWP FWP 0001193125-24-079032 333-265107 24792492 34 61209
2024-03-26 424B5 424B5 0001193125-24-077675 333-265107 24784321 33 522708
2024-03-25 10-K 10-K 0000950170-24-035912 001-38938 24779274 34 11767600 1 1
2024-03-25 8-K 8-K 7.01,9.01 0001193125-24-076478 001-38938 24779273 34 3220217 1 1
2024-03-25 8-K 8-K 2.02,9.01 0000950170-24-035908 001-38938 24779171 34 350240 1 1
2024-03-19 4 xslF345X05/form4-03202024_120350.xml 0001415889-24-008690 9416
2024-03-19 4 xslF345X05/form4-03202024_120307.xml 0001415889-24-008689 9420
2024-03-19 4 xslF345X05/form4-03202024_120349.xml 0001415889-24-008686 9684
2024-03-19 4 xslF345X05/form4-03202024_120318.xml 0001415889-24-008683 9383
2024-03-19 4 xslF345X05/form4-03202024_120354.xml 0001415889-24-008681 9706
2024-03-05 4 xslF345X05/form4-03052024_090335.xml 0001415889-24-006623 9271
2024-03-01 144 xsl144X01/primary_doc.xml 0001950047-24-001653 001-38938 24710334 33 6813
2024-02-26 SC 13G/A COWEN FINANCIAL PRODUCTS LLC 0001085146-24-001540 005-91051 24674657 34 27364
2024-02-26 SC 13G COWEN FINANCIAL PRODUCTS LLC 0001085146-24-001539 005-91051 24674651 34 27302
2024-02-15 4 xslF345X05/form4-02152024_090236.xml 0001415889-24-003897 7040
2024-02-14 SC 13G/A SC 13G/A 0001104659-24-023778 005-91051 24638915 34 102402
2024-02-14 SC 13G/A STOKE THERAPEUTICS, INC. 0000902664-24-001610 005-91051 24633033 34 64836
2024-02-14 SC 13G/A STOKE THERAPEUTICS, INC. 0000902664-24-001571 005-91051 24632360 34 64487
2024-02-09 SC 13G/A MS AMENDMENT 0000895421-24-000165 005-91051 24614170 34 17612
2024-02-09 SC 13G/A filing.txt 0000315066-24-001457 005-91051 24612039 34 8252
2024-02-05 4 xslF345X05/form4-02052024_090232.xml 0001415889-24-002531 5399
2024-02-01 144 xsl144X01/primary_doc.xml 0001950047-24-000596 001-38938 24587660 33 5518
2024-01-08 8-K 8-K 7.01,8.01,9.01 0001193125-24-003939 001-38938 24518440 34 9100876 1 1
2024-01-04 4 FORM 4 SUBMISSION 0001209191-24-000801 5751
2024-01-02 144 xsl144X01/primary_doc.xml 0001950047-24-000023 001-38938 24502866 33 4809
2023-12-14 8-K 8-K 1.01,2.03 0001193125-23-295456 001-38938 231487116 34 145870 1 1
2023-12-05 4 FORM 4 SUBMISSION 0001209191-23-057410 13823
2023-12-05 4 FORM 4 SUBMISSION 0001209191-23-057407 13828
2023-12-05 4 FORM 4 SUBMISSION 0001209191-23-057403 8352
2023-12-05 4 FORM 4 SUBMISSION 0001209191-23-057396 8330
2023-12-05 4 FORM 4 SUBMISSION 0001209191-23-057387 11120
2023-12-05 SC TO-I/A SC TO-I/A 0001193125-23-289154 005-91051 231466642 34 19042
2023-12-01 8-K 8-K 7.01,9.01 0001193125-23-286862 001-38938 231457707 34 196901 1 1
2023-11-17 SC TO-I/A SC TO-I/A 0001193125-23-279830 005-91051 231419382 34 98796
2023-11-17 CORRESP filename1.htm 0001193125-23-279827 40169
2023-11-16 UPLOAD filename1.pdf 0000000000-23-012558 56292
2023-11-09 SC TO-I/A SC TO-I/A 0001193125-23-274539 005-91051 231393011 34 34117
2023-11-07 10-Q 10-Q 0000950170-23-060224 001-38938 231383638 34 7134921 1 1
2023-11-07 8-K 8-K 2.02,9.01 0000950170-23-059756 001-38938 231381513 34 468244 1 1
2023-11-06 SC 13G STOKE THERAPEUTICS, INC. 0000902664-23-005344 005-91051 231380585 34 67250
2023-11-02 SC TO-I SC TO-I 0001193125-23-268930 005-91051 231370314 34 18395369
2023-10-26 8-K 8-K 5.07 0001193125-23-264160 001-38938 231350885 34 145969 1 1
2023-09-28 DEF 14A DEF 14A 0001193125-23-245609 001-38938 231289508 34 580710
2023-09-20 4 FORM 4 SUBMISSION 0001209191-23-050170 5488
2023-09-20 3 FORM 3 SUBMISSION 0001209191-23-050166 5922
2023-09-20 8-K 8-K 5.02,9.01 0001193125-23-238627 001-38938 231266885 34 161344 1 1
2023-09-18 PRE 14A PRE 14A 0001193125-23-236901 001-38938 231261229 34 580013
2023-09-08 4 FORM 4 SUBMISSION 0001209191-23-048770 7076
2023-08-07 10-Q 10-Q 0000950170-23-039050 001-38938 231147626 34 7981989 1 1
2023-08-07 8-K 8-K 2.02,9.01 0000950170-23-038733 001-38938 231145561 34 540274 1 1
2023-07-25 8-K 8-K 7.01,9.01 0001193125-23-192735 001-38938 231106439 34 4170669 1 1
2023-07-06 4 FORM 4 SUBMISSION 0001209191-23-041616 5376
2023-06-23 4 FORM 4 SUBMISSION 0001209191-23-039428 5386
2023-06-21 144 xsl144X01/primary_doc.xml 0001950047-23-001827 001-38938 231030091 33 4730
2023-06-20 8-K 8-K 5.07 0001193125-23-170114 001-38938 231024971 34 155897 1 1
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037539 5452
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037537 5454
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037535 5467
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037533 5467
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037532 5451
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037530 5429
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037529 5464
2023-06-05 4 FORM 4 SUBMISSION 0001209191-23-034648 5375
2023-05-24 DEFA14A DEFA14A 0001193125-23-153061 001-38938 23955100 34 15987
2023-05-08 4 FORM 4 SUBMISSION 0001209191-23-028111 4838
2023-05-04 10-Q 10-Q 0000950170-23-017839 001-38938 23888659 34 7661395 1 1
2023-05-04 8-K 8-K 2.02,9.01 0000950170-23-017454 001-38938 23886396 34 469865 1 1
2023-05-03 4 FORM 4 SUBMISSION 0001209191-23-027190 9570
2023-05-03 144 xsl144X01/primary_doc.xml 0001950047-23-000361 001-38938 23884876 33 6854
2023-04-27 ARS ARS 0001193125-23-122150 001-38938 23856922 34 8652665
2023-04-27 DEFA14A DEFA14A 0001193125-23-122102 001-38938 23856737 34 792068
2023-04-27 DEF 14A DEF 14A 0001193125-23-122085 001-38938 23856621 34 801836
2023-04-17 PRE 14A PRE 14A 0001193125-23-103615 001-38938 23823938 34 802045
2023-04-13 S-8 S-8 0001193125-23-100506 333-271237 23818360 33 343279
2023-03-22 S-8 S-8 0001193125-23-076715 333-270744 23753190 33 77492
2023-03-17 4 FORM 4 SUBMISSION 0001209191-23-019676 8087
2023-03-17 4 FORM 4 SUBMISSION 0001209191-23-019669 8064
2023-03-17 4 FORM 4 SUBMISSION 0001209191-23-019662 8070
2023-03-17 4 FORM 4 SUBMISSION 0001209191-23-019656 8061
2023-03-17 4 FORM 4 SUBMISSION 0001209191-23-019653 8037
2023-03-17 3 FORM 3 SUBMISSION 0001209191-23-019564 10461
2023-03-15 8-K 8-K 7.01,8.01,9.01 0001193125-23-070652 001-38938 23733257 34 175618 1 1
2023-03-06 10-K 10-K 0001564590-23-003175 001-38938 23708934 34 13196790 1 1
2023-03-06 8-K 8-K 2.02,9.01 0001564590-23-003162 001-38938 23707531 34 507954 1 1
2023-02-14 SC 13G/A STOKE THERAPEUTICS, INC. 0000902664-23-001724 005-91051 23623858 34 65182
2023-02-10 SC 13G MS INITIAL 0000895421-23-000192 005-91051 23609631 34 17508
2023-02-09 SC 13G/A filing.txt 0000315066-23-002041 005-91051 23605025 34 8040
2023-02-09 SC 13G/A SCHEDULE 13G/A 0001104659-23-017029 005-91051 23604298 34 13018
2023-02-07 4 FORM 4 SUBMISSION 0001209191-23-007597 7420
2023-02-03 SC 13G/A SC 13G/A 0001104659-23-010642 005-91051 23587314 34 90476
2023-02-03 8-K 8-K 5.03,9.01 0001193125-23-024123 001-38938 23585781 34 372571 1 1
2023-02-02 4 FORM 4 SUBMISSION 0001209191-23-006397 8446
2023-01-25 SC 13G/A COWEN FINANCIAL PRODUCTS LLC 0001085146-23-000369 005-91051 23552428 34 27272
2023-01-09 8-K 8-K 7.01,8.01,9.01 0001193125-23-004192 001-38938 23516704 34 8879696 1 1
2022-12-09 4 FORM 4 SUBMISSION 0001209191-22-060548 5494
2022-12-09 4 FORM 4 SUBMISSION 0001209191-22-060547 5499

Latest XBRL company facts

One latest value per concept from companyfacts (204 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 65.41M 2026-10-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
dei EntityPublicFloat Entity Public Float USD 592.00M 2025-06-30 2025 FY 10-K 2026-03-16 0001193125-26-108362
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 9.56M 2025-01-01 2025-12-31 DEF 14A 2026-04-22 0001193125-26-170362
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 2.05M 2025-01-01 2025-12-31 DEF 14A 2026-04-22 0001193125-26-170362
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 343.88 2025-01-01 2025-12-31 DEF 14A 2026-04-22 0001193125-26-170362
ffd NetFeeAmt NetFeeAmt USD 8,063 2026-07-31 S-8 2026-08-03 0001193125-26-330706
ffd NrrtvMaxAggtOfferingPric NrrtvMaxAggtOfferingPric USD 200.00M 2026-07-31 424B5 2026-08-03 0001193125-26-330792
ffd TtlFeeAmt TtlFeeAmt USD 8,063 2026-07-31 S-8 2026-08-03 0001193125-26-330706
ffd TtlOfferingAmt TtlOfferingAmt USD 58.38M 2026-07-31 S-8 2026-08-03 0001193125-26-330706
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-07-31 S-8 2026-08-03 0001193125-26-330706
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-07-31 424B5 2026-08-03 0001193125-26-330792
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 4.03M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 8.54M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap AccruedEmployeeBenefitsCurrent Accrued Employee Benefits, Current USD 10.17M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 5.74M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 10.15M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -1.05M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 1.04B 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 11.03M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 378,000 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-23 0001564590-20-012202
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 30.59M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 13.56M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap Assets Assets USD 406.69M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap AssetsCurrent Assets, Current USD 354.42M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 2,000 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 1.05M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 252.57M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 251.52M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 211.92M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Debt Securities, Available-for-sale, Noncurrent USD 39.60M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 1.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 107.27M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 233.25M 2019-09-30 2019 Q3 10-Q 2019-11-12 0001564590-19-042891
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 110.99M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 26.05M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 300.00M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 64.81M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 64.81M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap CommonStockValue Common Stock, Value, Issued USD 6,000 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -186.86M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap ConversionOfStockAmountIssued1 Conversion of Stock, Amount Issued USD 3.00M 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-23 0001564590-20-012202
us-gaap DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Debt Securities, Available-for-sale, Allowance for Credit Loss USD 0 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap DeferredCostsCurrent Deferred Costs, Current USD 402,000 2024-03-31 2024 Q1 10-Q 2024-05-06 0000950170-24-053535
us-gaap DeferredFinanceCostsCurrentNet Debt Issuance Costs, Current, Net USD 117,000 2021-12-31 2022 FY 10-K 2023-03-06 0001564590-23-003175
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 6.36M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap DeferredRevenueNoncurrent Deferred Revenue, Noncurrent USD 4.45M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 161.14M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 28.92M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 66.00M 2021-12-31 2022 Q3 10-Q 2022-11-14 0001564590-22-037497
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 87.59M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 2.08M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 29.72M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 161.14M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost USD 1.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap Depreciation Depreciation USD 1.35M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -2.81 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.66 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-10 0001564590-22-019268
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -2.81 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure 0.485 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure -0.01 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.155 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.007 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.09 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure 0.888 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 83.40M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 29.91M 2025-01-01 2025-06-30 2025 Q2 10-Q 2025-08-12 0000950170-25-107332
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -185.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 573,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap IncomeTaxPaidFederalAfterRefundReceived IncomeTaxPaidFederalAfterRefundReceived USD 573,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap IncomeTaxPaidStateAndLocalAfterRefundReceived IncomeTaxPaidStateAndLocalAfterRefundReceived USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD -3.34M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -1.45M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 7,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 1.07M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 53,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 6.11M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities USD -2.06M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-07 0000950170-23-060224
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 2.61M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap IncreaseDecreaseInDeferredLiabilities Increase (Decrease) in Deferred Liabilities USD 28,000 2019-01-01 2019-12-31 2020 FY 10-K 2021-03-09 0001564590-21-011760
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD -8.05M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 11.65M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap InterestExpense Interest Expense USD 61,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap InterestIncomeExpenseNonoperatingNet Interest Income (Expense), Nonoperating, Net USD 10.56M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap InterestReceivableCurrent Interest Receivable, Current USD 1.53M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 10.63M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap LeaseAndRentalExpense Operating Leases, Rent Expense USD 1.10M 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-23 0001564590-20-012202
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 2.05M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 699,000 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 473,000 2025-09-30 2025 Q3 10-Q 2025-11-04 0001193125-25-264720
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 533,000 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 532,000 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 815,000 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 124,000 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap Liabilities Liabilities USD 54.10M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 406.69M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap LiabilitiesCurrent Liabilities, Current USD 48.98M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap LiabilitiesNoncurrent Liabilities, Noncurrent USD 5.13M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 156.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 49.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -179.85M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -185.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 10.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap OperatingExpenses Operating Expenses USD 222.97M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -196.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 86.60M 2026-01-21 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap OperatingLeaseImpairmentLoss Operating Lease, Impairment Loss USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 1.92M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 1.24M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 680,000 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 1.23M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 1.18M 2020-12-31 2020 FY 10-K 2021-03-09 0001564590-21-011760
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 1.10M 2020-12-31 2020 FY 10-K 2021-03-09 0001564590-21-011760
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 81,000 2019-09-30 2019 Q3 10-Q 2019-11-12 0001564590-19-042891
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 81,000 2019-12-31 2020 Q3 10-Q 2020-11-12 0001564590-20-053586
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 81,000 2020-12-31 2020 FY 10-K 2021-03-09 0001564590-21-011760
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 281,000 2019-09-30 2019 Q3 10-Q 2019-11-12 0001564590-19-042891
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.1 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 28,000 2021-09-30 2021 Q3 10-Q 2021-11-08 0001564590-21-055240
us-gaap OtherAssetsCurrent Other Assets, Current USD 7.56M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD -1.59M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -1.59M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap OtherLiabilitiesCurrent Other Liabilities, Current USD 1.75M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 681,000 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 333,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap PaymentsOfFinancingCosts Payments of Financing Costs USD 179,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-10 0001564590-22-009634
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 306,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-10 0001564590-22-009634
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 103.97M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 5.18M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2019-06-21 2020 FY 10-K 2021-03-09 0001564590-21-011760
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2019-06-21 2020 FY 10-K 2021-03-09 0001564590-21-011760
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2019-12-31 2019 FY 10-K 2020-03-23 0001564590-20-012202
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2020-12-31 2020 FY 10-K 2021-03-09 0001564590-21-011760
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 12.55M 2022-09-30 2022 Q3 10-Q 2022-11-14 0001564590-22-037497
us-gaap PrepaidExpenseCurrent Prepaid Expense, Current USD 17.60M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 105.40M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-10 0001564590-22-009634
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 116.00M 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-23 0001564590-20-012202
us-gaap ProceedsFromPaymentsForOtherFinancingActivities Proceeds from (Payments for) Other Financing Activities USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-25 0000950170-24-035912
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 158.65M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 1,000 2019-01-01 2019-12-31 2020 FY 10-K 2021-03-09 0001564590-21-011760
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 8.64M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 1.41M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -185.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap ProFormaWeightedAverageSharesOutstandingDiluted Pro Forma Weighted Average Shares Outstanding, Diluted shares 3.70M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 13.29M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 8.21M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 149.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap RestrictedCashAndCashEquivalents Restricted Cash and Cash Equivalents USD 721,000 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 494,000 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 3.23M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -682.98M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap Revenues Revenues USD 26.81M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 5.08M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-10 0001564590-22-009634
us-gaap SegmentReportingOtherItemAmount SegmentReportingOtherItemAmount USD -13.71M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap SellingGeneralAndAdministrativeExpense Selling, General and Administrative Expense USD 73.97M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 30.59M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.79 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 0.81 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.8 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.027 2018-01-01 2018-06-30 2019 Q2 10-Q 2019-08-14 0001564590-19-032126
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.046 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.038 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 105.55M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 5.11M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 11.45 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 12.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period shares 281,722 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 178,004 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-09 0001564590-21-011760
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 21.15 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-09 0001564590-21-011760
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 868,987 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 531,869 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 11.53 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 184.39M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 10.15M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 13.84 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 502,638 2018-12-31 2019 FY 10-K 2020-03-23 0001564590-20-012202
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 8.59 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price USD/shares 15.09 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 10.99 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 15.94 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 352.59M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.101 2019-06-05 2019-06-06 2020 FY 10-K 2021-03-09 0001564590-21-011760
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 1.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 941,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 149.45M 2019-04-01 2019-06-30 2019 Q3 10-Q 2019-11-12 0001564590-19-042891
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 3.52M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap SubleaseIncome Sublease Income USD 400,000 2025-09-01 2025-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 0 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD -4.50M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108362
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 65.83M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 37.45M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-10 0001564590-22-019268
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 65.83M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-445326

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →